New combo therapy targets rare liver cancer in early trial
Disease control
Not yet recruiting
This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma. The goal is to see if this treatment can shrink tu…
Phase: PHASE2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated May 17, 2026 08:02 UTC